Skip to NavigationSkip to content

Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer

Published on 12/12/19 at 03:27pm

Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in risk of death compared to fulvestrant on its own in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

This data was published in The New England Journal of Medicine (NEJM).

Jeff Engelman, Global Head of Oncology Research at Novartis Institutes for BioMedical Research, said: “These data show that treatment with Kisqali gives women with HR+/HER2- advanced breast cancer a chance for more life – whether they are treatment naïve or have had prior therapy. Pre-clinical data show that Kisqali is distinct from other CDK4/6 inhibitors in its ability to more selectively target and inhibit CDK4.”

The NEJM publication includes subgroup analyses according to a line of therapy. At 42 months, survival rates among patients who received first-line therapy were 66.9% with Kisqali plus fulvestrant vs 56.3% with fulvestrant alone. The median survival rates among patients in the early-relapse and second-line subgroup was 40.2 months with Kisqali plus fulvestrant and 32.5 months with fulvestrant alone.

A post-hoc survival analysis based on prior endocrine therapy demonstrated that Kisqali plus fulvestrant had a 36% reduction in rick in death for those who did not receive any previous endocrine therapy, a 30% reduction in risk of death in those who were endocrine resistant and a 26% reduction in risk of death in those who were endocrine sensitive.

Kisqali is a prescription medicine that is used in combination with an aromatase inhibitor that is the first hormonal-based therapy to treat pre and postmenopausal women.

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches